Companies /Healthcare

Senseonics Holdings Inc

NYSE MKT: SENS Medical Devices
$10.93
▲ $0.35 (+3.31%) today
Markets open · 4:02pm ET

SENS at a Glance

Valuation
Market cap
$579.6M
Profitability
Revenue (TTM)
$60.0M
Profit margin
-204.2%
EPS (TTM)
$-2.27
Price
52-week range
$5 – $14
Street target
$15.08

Headquartered in Germantown, MD Fiscal year ends December NYSE MKT: SENS senseonics.com

About Senseonics

Senseonics Holdings, Inc. is a medical device company focused on diabetes care through long-term implantable continuous glucose monitoring (CGM). Its commercial product is Eversense 365, a one-year CGM system. The system pairs a small sensor inserted under the skin by a healthcare provider with a removable smart transmitter. The transmitter sends real-time glucose data to a mobile app or to an integrated automated insulin delivery (AID) system. Eversense 365 is cleared in the U.S. and approved in Europe for adults with diabetes aged 18 and older, and is sold by prescription in the U.S. and select European markets.

The company now runs its commercial operations in-house globally. This follows a transition away from partner-led distribution, which is visible in a sharp decline in related-party revenue. Its commercial model includes:
- Direct-to-consumer and healthcare-provider outreach
- U.S. patient assistance programs
- EON Care, a network of more than 100 inserters that performs a growing share of sensor insertion procedures

Senseonics is expanding pump compatibility through integrations with Sequel's twiist and, as planned, Beta Bionics' iLet Bionic Pancreas. Its pipeline includes Gemini, which is in clinical trials, and Freedom, an investigational next-generation CGM designed to communicate directly with a mobile device without an on-body component, now in a first-in-human study. The company is funded by cash and short-term investments and a Hercules Capital debt facility. Updated

Latest Activity

SENSSenseonics
Q3 2026
EPS
-$0.50
est -$0.52+4.2%
Revenue
$20M
est $16M+20.8%

Taking U.S. Eversense 365 sales in-house lifted gross margin to roughly 62% from 43% a year earlier. Revenue beat expectations and management raised full-year guidance to $68 million to $70 million.

Quarterly EPS — reported vs estimate

SENS Coverage

8:05am ET
Investing

Meme Stocks Make a Comeback

The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.

Chris Lange

Frequently Asked Questions

What does Senseonics do?

Senseonics Holdings, Inc. is a medical device company focused on diabetes care through long-term implantable continuous glucose monitoring (CGM). Its commercial product is Eversense 365, a one-year CGM system.

What is the SENS stock price target?

The Wall Street consensus 12-month price target for SENS is $15.08.